{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:31:22Z","timestamp":1793745082024,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"RSF","doi-asserted-by":"publisher","award":["\\u211623-15-00327"],"award-info":[{"award-number":["\\u211623-15-00327"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.042","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:31:55Z","timestamp":1777606315000},"page":"1117.e1-1117.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0114","authenticated-orcid":false,"given":"I","family":"Moiseev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Drokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Kitaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Rudakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-5581","authenticated-orcid":false,"given":"Maria","family":"Barabanshchikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0506-6438","authenticated-orcid":false,"given":"Daria","family":"Chernyshova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Rodionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Svetkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Lapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-453X","authenticated-orcid":false,"given":"Irina","family":"Kholopova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Vasilyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7762-0107","authenticated-orcid":false,"given":"Yulia","family":"Vlasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-0340","authenticated-orcid":false,"given":"Dmitrii","family":"Zhogolev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parovichnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0051","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.04.042_bib0001","doi-asserted-by":"crossref","unstructured":"Piemontese S, Ciceri F, Labopin M, et al. Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29(5):1069-75.","DOI":"10.1038\/leu.2014.336"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.042_bib0002","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.2024024038","article-title":"Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity","volume":"144","author":"Lum","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.042_bib0003","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","article-title":"ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","article-title":"PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation","volume":"14","author":"Penack","year":"2024","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.jtct.2026.04.042_bib0005","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"BMT CTN 1703 investigators. post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2026.04.042_bib0052","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.042_bib0053","doi-asserted-by":"crossref","first-page":"52","DOI":"10.18620\/ctt-1866-8836-2017-6-4-52-59","article-title":"Single-agent post-transplantation cyclophosphamide versus calcineurin-based graft-versus-host disease prophylaxis in matched related bone marrow transplantation","volume":"6","author":"Moiseev","year":"2017","journal-title":"Cell Ther Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.042_bib0006","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ejh.12541","article-title":"OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.042_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0009","doi-asserted-by":"crossref","first-page":"40.e132","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcyt.2023.10.008","article-title":"Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis","volume":"26","author":"Escribano-Serrat","year":"2024","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-023-01450-4","article-title":"Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP\/EBMT","volume":"16","author":"Nagler","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.042_bib0054","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.042_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.042_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41409-022-01879-0","article-title":"First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens","volume":"58","author":"Moiseev","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.042_bib0015","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.042_bib0016","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.042_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2026.04.042_bib0018","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s43018-023-00607-x","article-title":"Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms","volume":"4","author":"Grockowiak","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000506758","article-title":"A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis","volume":"144","author":"Morozova","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2026.04.042_bib0020","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212NIH\u2212CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.042_bib0021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"REACH3 investigatnal institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign guidelines committee including the pediatric subgroup. surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.042_bib0023","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.042_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.042_bib0025","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Inter"},{"key":"10.1016\/j.jtct.2026.04.042_bib0026","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.042_bib0027","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"29","key":"10.1016\/j.jtct.2026.04.042_bib0028","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jtct.2026.04.042_bib0029","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.042_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101076","article-title":"Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"60","author":"Muskens","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2026.04.042_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.042_bib0032","article-title":"Phase II study of peri- and post-transplant ruxolitinib for patients with myelofibrosis receiving allogeneic hematopoietic cell transplantation","volume":"2","author":"Hobbs","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"20","key":"10.1016\/j.jtct.2026.04.042_bib0033","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.2024028005","article-title":"Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT","volume":"145","author":"DeFilipp","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.04.042_bib0034","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2024-206823","article-title":"A multicenter randomized controlled trial of low-dose ruxolitinib for gvhd prophylaxis in haploidentical hematopoietic stem cell transplantation [abstract]","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.042_bib0035","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0036","doi-asserted-by":"crossref","first-page":"55","DOI":"10.18620\/ctt-1866-8836-2025-14-2-55-86","article-title":"Recommendations of Russian society for hematopoietic stem cell transplantation, gene and cell therapy for diagnosis and treatment of graft-versus-host disease","volume":"14","author":"Moiseev","year":"2025","journal-title":"Cell Ther Transplant"},{"issue":"47","key":"10.1016\/j.jtct.2026.04.042_bib0037","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"10.1016\/j.jtct.2026.04.042_bib0038","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/JCO-24-02477","article-title":"Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study","volume":"43","author":"Zeiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.042_bib0039","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/bloodadvances.2022007026","article-title":"Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs","volume":"7","author":"Fletcher","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.042_bib0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.042_bib0041","article-title":"Impact of the COVID-19 pandemic mitigation strategies on cancer treatment trials: a meta-analysis of industry and national cancer institute studies","volume":"2","author":"Unger","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"3-4","key":"10.1016\/j.jtct.2026.04.042_bib0042","doi-asserted-by":"crossref","first-page":"30","DOI":"10.18620\/ctt-1866-8836-2021-10-3-4-30-37","article-title":"Journey of a hematopoietic stem cell transplantation center through COVID-19 pandemic: one-year experience","volume":"10","author":"Siniaev","year":"2021","journal-title":"Cell Ther Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0043","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41409-025-02766-0","volume":"61","author":"Vydra","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.042_bib0044","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jtct.2026.04.042_bib0045","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.042_bib0046","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.042_bib0047","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.042_bib0048","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.V73.7.2018.2018","article-title":"Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation","volume":"73","author":"Holler","year":"1989","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.042_bib0049","doi-asserted-by":"crossref","first-page":"330.e1","DOI":"10.1016\/j.jtct.2021.01.010","article-title":"Serotherapy-free regimen improves non-relapse mortality and immune recovery among the recipients of \u03b1\u03b2 tcell-depleted haploidentical grafts: retrospective study in childhood leukemia","volume":"27","author":"Shelikhova","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.042_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:32Z","timestamp":1788987152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003337"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.042","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}